Tag: Non-Small Cell Lung Cancer
Consistent efficacy of osimertinib in Chinese and global population
Promising efficacy of neoadjuvant osimertinib in EGFR-mutated NSCLC
Pro-inflammatory tumour profile predicts complete pathological response to neoadjuvant chemoimmunotherapy
Furmonertinib outperforms gefitinib as first-line therapy in patients with EGFR-mutated NSCLC
Second-line oritinib demonstrated potential clinical benefit in advanced EGFR-mutated NSCLC
Updated results confirm efficacy and safety of entrectinib in patients with NTRK fusion-positive NSCLC
ROS1 rearrangement-targeting unecritinib is a potential new first-line strategy
Savolitinib is effective in patients with MET-mutated NSCLC
Sintilimab plus chemotherapy improves OS in treatment-naïve, stage III–IV non-squamous NSCLC
Updated results of CameL-sq trial confirm benefit of camrelizumab
No long-term benefit of adding ipilimumab to pembrolizumab in metastatic NSCLC
In concurrent CRT for stage III, unresectable NSCLC, performance status is better with proton therapy than photon therapy
No improved prognosis for concurrent versus sequential immune checkpoint inhibition and CRT in unresectable NSCLC
Durvalumab after sequential CRT safe in stage III, unresectable NSCLC
Immunotherapy delays deterioration in health-related quality of life in metastatic NSCLC
Robust anticancer activity of trastuzumab deruxtecan in HER2-mutated NSCLC
Adjuvant atezolizumab lowers relapse rate in resected NSCLC
TCR clonality predicts pembrolizumab response in NSCLC
ESMO 2021 Highlights Podcast
Baseline CD8+ T-cells predict NSCLC immunotherapy safety
Genomic profiling of NSCLC may be predictive of immunotherapy response
New preoperative classification scheme proposed for oligometastatic NSCLC
Discrepancies and lack of guideline adherence in EGFR+ NSCLC treatment
Atezolizumab promising for treating NSCLC brain metastases
Pembrolizumab shows potential in TKI-resistant EGFR+ NSCLC, not ALK+
Real-world data shows inferior survival compared with IMpower150 results
NSCLC metastases also benefit from nivolumab + ipilimumab + chemo
Neoadjuvant nivolumab plus chemotherapy improves surgical outcomes in NSCLC
Immune-related adverse events are associated with efficacy of atezolizumab in patients with advanced NSCLC
Sustained efficacy of nivolumab/ipilimumab plus 2 cycles of chemotherapy in NSCLC
Patritumab deruxtecan (HER3-DXd) in EGFR TKI-resistant NSCLC
Durvalumab after chemoradiation proven safe in elderly NSCLC patients
Doubling overall survival in US veterans with stage 3 non-small cell lung cancer
5-year PACIFIC data hold strong in NSCLC
Early-Stage NSCLC: Promising Data for Neoadjuvant Durvalumab With Stereotactic Body Radiotherapy
Novel imaging biomarkers predict benefit in stage 3 NSCLC treated with chemoradiation and durvalumab
Phase III ADAURA Trial: CNS Recurrences slashed for NSCLC
Atezolizumab with SABR for high-risk early-stage NSCLC: initial results
4-year PACIFIC data hold strong in NSCLC
Amivantamab/lazertinib benefits patients with EGFR-mutated NCSLC
No advantage of post-operative radiotherapy in patients with stage IIIA N2 NSCLC
Higher thrombotic risk in NSCLC patient with ALK rearrangement
Adjuvant osimertinib in NSCLC: practice changing ADAURA trial
Thoracic cancers versus COVID-19
Cancer treatment with checkpoint inhibitors in RA patients?
Fever during immunotherapy for NSCLC associated with shorter PFS
NSCLC: A new way to evaluate hilar and mediastinal lymph nodes
Mixed data: AMG 510 in tumours with KRASG12C
Ceritinib in ALK+ NSCLC brain metastases
Frontline ipilimumab/nivolumab improves OS in advanced NCLSC
First-line osimertinib significantly lengthens OS in NSCLC
Liquid biopsy to decide the best treatment for NSCLC
First-line pembrolizumab monotherapy offers durable OS benefit vs chemotherapy in NSCLC patients with high PD-L1 expression
Five-fold increase of OS at 5 years with nivolumab vs docetaxel
